Hinterland Metals Inc. Signs Letter of Intent with Novamind Ventures Inc.

Hinteland Metals Inc .与 Novachem Ventures Inc .签署意向书。

2020-07-09 09:31:14 CFN Media Group

本文共3805个字,阅读需10分钟

July 6, 2020 This news release is intended for distribution in Canada only and is not authorized for distribution to United States newswire services or for dissemination in the United States. TORONTO, ON / ACCESSWIRE / July 6, 2020 / Hinterland Metals Inc. (the”Company“or”Hinterland“) is pleased to announce that it has signed a binding letter of intent dated July 3, 2020 (the “LOI”) pursuant to which the Company will acquire (the “Proposed Transaction”) all of the outstanding shares of Novamind Ventures Inc. (“Novamind”), a company that invests in the infrastructure that drives the world’s leading psychedelic clinics and retreats. Novamind seeks to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry. It is intended that the combined company (the “Resulting Issuer”) will carry on the business of Novamind. Pursuant to the Proposed Transaction, the Company or its wholly-owned subsidiary will amalgamate with Novamind (the “Amalgamation”) and the shareholders of Novamind will exchange their common shares of Novamind (the “Novamind Shares”) for common shares of the Company (the “Hinterland Shares”). Novamind is currently undertaking a non-brokered private placement (the “Financing”) of Novamind Shares at a price of $0.10 per Novamind Share for gross proceeds of $3,000,000 to be completed prior to the closing of the Proposed Transaction. Prior to the Amalgamation, Hinterland will effect a consolidation (the “Hinterland Consolidation”) of the issued and outstanding Hinterland Shares. Under the Hinterland Consolidation, the Hinterland Shares will be consolidated on a basis that results in the holders of the Hinterland Shares holding post-Hinterland Consolidation Hinterland Shares (the “Hinterland Consolidated Shares”) having a value of $1,300,000 calculated based on the Financing price, provided that Hinterland has net cash and marketable securities of minimum $300,000at closing (less costs incurred in connection with the Proposed Transaction). Following the Hinterland Consolidation and pursuant to the Amalgamation, the holders of Novamind Shares immediately prior to the completion of the Amalgamation will each receive, for every four (4) Novamind Shares held immediately prior to the completion of the Amalgamation, one (1) Hinterland Consolidated Share (the “Exchange Ratio”). Convertible securities of Novamind (the “Novamind Convertible Securities”) will either automatically adjust in accordance with the terms thereof such that following the completion of the Amalgamation, the holders thereof shall acquire Hinterland Consolidated Shares in lieu of Novamind Consolidated Shares or will be replaced with equivalent convertible securities of Hinterland entitling the holders thereof to acquire Hinterland Consolidated Shares in lieu of Novamind Consolidated Shares, and otherwise bearing the same terms as the Novamind Convertible Securities they replace. As a condition of the Proposed Transaction, Hinterland will apply to list the Hinterland Consolidated Shares on the Canadian Securities Exchange (the “CSE”). Prior to the closing of the Proposed Transaction, Hinterland will change its name to “Novamind Inc.”, or such other name as may be agreed upon by the parties. Board and Management Changes It is the parties’ intention that upon closing of the Proposed Transaction, the board of directors and officers of the Resulting Issuer be reconstituted to be comprised of Yaron Conforti (Chief Executive Officer and Director), Jesse Kaplan (Director), Sruli Weinreb (Director), and Chuck Rifici (Director), all in a manner that complies with applicable securities and corporate laws (the “Board and Management Rollover”). Upon and subject to the completion of the Cedar Acquisition (as defined below) it is anticipated that Dr. Reid Robison will also join the board of Novamind and will be appointed to the board of the Resulting Issuer as part of the Board and Management Rollover. Closing Conditions The completion of the Proposed Transaction remains subject to a number of terms and conditions, including, among other things (1) a change in the name of Hinterland to “Novamind Inc.” or such other name as may be approved by Novamind and acceptable to applicable regulatory authorities; (2) receipt of conditional approval of the CSE for the listing of the Hinterland Consolidated Shares; (3) all required approvals and consents for the Proposed Transaction, (4) completion of the Hinterland Consolidation; (5) the completion of the Board and Management Rollover; (6) completion of the Financing; and (7) approval of the Amalgamation by Novamind shareholders. About Novamind Novamind was founded in May 2019 in Toronto, Canada. Ongoing clinical trials approved by the U.S. Food and Drug Administration (“FDA”) are currently evaluating the safety and efficacy of MDMA-assisted psychotherapy (to treat PTSD) and psilocybin-assisted psychotherapy (to treat depression), and if approved, will require specialized infrastructure to facilitate patient treatment. Novamind seeks to accelerate research and innovation in psychedelic medicine by investing in the people, science and technology required for a regulated psychedelics industry. Until such time that the FDA approves new psychedelic medicines, Novamind invests and operates exclusively in those jurisdictions with established legal regulations for the use of psychedelics. Novamind was an early mover in 2019 and made two strategic investments in industry leading psychedelic retreats and clinics: (A) a €750,000 (CAD $1,137,623) investment in Synthesis Institute B.V. (“Synthesis”), a Netherlands-based psychedelics retreat offering an interdisciplinary approach to safe, legal psilocybin experiences. The investment in Synthesis was funded in cash and closed in multiple tranches beginning in November 2019 with the final tranche completed in March 2020; and (B) a letter of intent to purchase (the “Cedar Acquisition”) 100% of the assets of Cedar Psychiatry LLC and Cedar Clinical Research LLC (collectively, “Cedar”), a leading provider of psychedelic-assisted psychotherapy and research, based in the United States. Cedar operates three psychiatry clinics specialized in ketamine-assisted psychotherapy, and a dedicated research center that conducts novel clinical trials. Novamind’s acquisition of Cedar is expected to close prior to the completion of the Proposed Transaction. The purchase price for the Cedar acquisition is $3,050,000 consisting of 5,125,000 Novamind Consolidated Shares (as defined below) to be issued at a deemed price of $0.40 per share and cash payments totaling $1,000,000 to be paid over 12 months from closing of the Cedar Acquisition. Novamind’s investment in Synthesis and its pending acquisition of Cedar provide Novamind with access to proprietary resources including psychedelic-assisted psychotherapy protocols, industry-leading data, patient screening tools, leading facilitators and scientific advisors. Utilizing these best practices and partnering with leading practitioners in the psychedelic space, Novamind is building a network of clinics and retreats offering people access to safe, legal psychedelic experiences while advancing research for psychedelic medicine. About Hinterland Hinterland is an unlisted Canadian public company, reporting in the provinces of British Columbia, Alberta and Quebec. For additional information please contact: Hinterland Metals Inc. 1 Adelaide Street East, Suite 801 Toronto, Ontario M5C 2V9 Attention: Binyomin Posen, Director, Chief Executive Officer, and Chief Financial Officer Email: [email protected] ON BEHALF OF THE BOARD Binyomin Posen CEO, CFO & Director The securities of the Company have not, nor will they be registered under the United States Securities Act of 1933, as amended, and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons in the absence of U.S. registration or an applicable exemption from the U.S. registration requirements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in the United States or in any other jurisdiction in which such offer, solicitation or sale would be unlawful. The CSE has not in any way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release. All information contained in this news release with respect to Hinterland was supplied by the Company and all information in this news release with respect to Novamind, Synthesis and Cedar was supplied by Novamind, for inclusion herein, and Hinterland and its directors and officers have relied on Novamind for any information concerning such parties. This news release contains forward-looking statements relating to the timing and completion of the Proposed Transaction, the future operations of the Company, Novamind and the Resulting Issuer and other statements that are not historical facts. Forward-looking statements are often identified by terms such as “will”, “may”, “should”, “anticipate”, “expects” and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the Proposed Transaction and the future plans and objectives of the Company, Novamind and the Resulting Issuer are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company, Novamind and the Resulting Issuer include the failure to satisfy the conditions to completion of the Proposed Transaction set forth above and other risks detailed from time to time in the filings made by the Company, Novamind and the Resulting Issuer under securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company, Novamind and the Resulting Issuer. As a result, the Company, Novamind and the Resulting Issuer cannot guarantee that the Proposed Transaction will be completed on the terms and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company, Synthesis, Novamind and the Resulting Issuer will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law. This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
2020年7月6日 本新闻稿仅供加拿大分发,无权分发给美国通讯社或在美国传播。 TOROTOONO , ON / ACCESSWIRE /2020年7月6日/ Hinteland Metals Inc .(以下简称“公司”或“ Hinteland ”)欣然宣布,其已签署日期为2020年7月3日的约束性意向书(以下简称“意向书”),据此,公司将收购 Novamend Ventures Inc .(以下简称“ Novamend ”)全部已发行股份(以下简称“建议交易”)。一家投资于基础设施的公司,推动全球领先的迷幻药诊所和诊所的发展。Novartmind 致力于通过投资于受监管的迷幻药行业所需的人员、科学和技术,加快迷幻药的研究和创新。拟由合并后的公司(“结果发行人”)承接 Novartmine 的业务。 根据建议交易,本公司或其全资附属公司将与新思维合并(「合并」),而新思维的股东将交换其于新思维的普通股(「新思维股份」),以换取本公司的普通股(「欣德兰股份」)。 Novmine 目前正在进行一项非经纪私募配售(“融资”),以每股 Novmine 股份0.10美元的价格进行,总收益为3,000,000美元,将在拟议交易结束前完成。 于合并前,欣德兰将对已发行及尚未发行的欣德兰股份进行合并(「欣德兰合并」)。根据 Hinteland 合并, Hinteland 股份将根据导致持有 Hinteland 合并后 Hinteland 股份(以下简称“ Hinteland 合并股份”)的持有人持有按融资价格计算的价值为1,300,000美元的 Hinteland 股份进行合并。前提是 Hinteland 在交易结束时的净现金和有价证券至少为300,000美元(减去与提议交易有关的费用)。 于欣德兰合并后及根据合并,紧接合并完成前,欣德心股份之持有人将各自就紧接合并完成前之每四(4)股欣德心股份收取一(1)欣德兰合并股份(「交换比率」)。Novartmine 的可转换证券(“ Novartmine 可转换证券”)将根据其条款自动调整,以便在合并完成后,其持有人应收购欣德兰综合股份以代替欣德心综合股份,或将被欣德兰的等值可换股证券所取代,使其持有人有权收购欣德兰综合股份以代替欣德心综合股份,并以其他方式承担与其取代的欣德心可换股证券相同的条款。 作为建议交易的一项条件, Hinteland 将申请将 Hinteland 合并股份在加拿大证券交易所(“ CSE ”)上市。建议交易完成前, Hinteland 将更名为“ Novartmind Inc ”,或双方可能商定的其他名称。 董事会及管理层变动 各方的意图是,在拟议交易结束时,将结果发行人的董事会和高级职员改组为由 Yaron Conforge (首席执行官和董事)、 Jesse Kaplan (董事)、 Sruli Weinreb (董事)和 Chuck Rifici (董事)组成。所有方式均符合适用的证券和公司法(“董事会和管理层滚转”)。在 Cedar Acquisition (定义见下文)完成后,预计 Reid Robison 博士还将加入 Novachem 董事会,并将作为董事会和管理滚动的一部分任命结果发行人董事会。 成交条件 完成建议交易仍须遵守多项条款及条件,包括除其他事项外:(1)欣德兰名称变更为“欣德心股份有限公司”,或可能由欣德心批准并为适用监管机构所接受的其他名称;(2)欣德兰合并股份上市获得 CSE 有条件批准;(3)对建议交易的所有必要批准和同意;(4)完成欣德兰合并;(5)完成董事会和管理层交接;(6)完成融资;(7)由欣德心股东批准合并。 关于 Novartmine 诺华公司于2019年5月在加拿大多伦多成立。目前正在进行的由美国食品药品监督管理局(Food and Drug Administration)(“ FDA ”)批准的临床试验正在评估 MDMA 辅助心理治疗(治疗 PTSD )和 psyclocin 辅助心理治疗(治疗抑郁症)的安全性和有效性,如果获得批准,将需要专门的基础设施来促进患者治疗。Novartmind 致力于通过投资于受监管的迷幻药行业所需的人员、科学和技术,加快迷幻药的研究和创新。在 FDA 批准新的迷幻药之前,诺华公司只在那些有关于使用迷幻药的既定法律法规的司法管辖区进行投资和运营。Novartmine 是2019年的先行者,在行业领先的迷幻药市场和诊所进行了两项战略投资: ( A )投资75万欧元(1,137,623加元)投资合成研究所 B.V .("合成"),一家设在荷兰的迷幻剂研究中心,提供一种跨学科的安全、合法的精神障碍经验。合成的投资以现金方式出资,并于2019年11月开始分多期完成,最后一期于2020年3月完成; ( B )一份购买 Cedar Psychiatry LLC 和 Cedar Clinical Research LLC (统称“ Cedar ”)100%资产的意向书(以下简称“ Cedar 收购”),一家美国领先的精神治疗和研究提供商。Cedar 经营着三家专门从事氯胺酮辅助心理治疗的精神病学诊所,以及一个专门从事新型临床试验的研究中心。诺华收购 Cedar 的交易预计将在拟议交易完成之前完成。Cedar 收购的收购价格为3,050,000美元,包括5,125,000股 Novachem 合并股份(定义见下文)将以每股0.40美元的确定价格发行,以及 Cedar 收购完成后12个月内将支付的总计1,000,000美元的现金支付。 Novartmine 对 Synthesis 的投资以及即将收购 Cedar 的计划,为 Novartmine 提供了获取专有资源的渠道,包括迷幻剂辅助心理治疗协议、行业领先数据、患者筛选工具、领先服务商和科学顾问。利用这些最佳做法,并与灵媒领域的领先从业者合作, Novartmine 正在建立一个诊所和诊所网络,为人们提供安全、合法的灵媒体验,同时推进灵媒医学研究。 关于欣特兰 Hinteland 是一家未上市的加拿大上市公司,在不列颠哥伦比亚省、艾伯塔省和魁北克省进行报告。 如需更多信息,请联系: 欣特兰金属公司。 1 Adelaide Street East , Suite 801 多伦多,安大略省 M5C 2V9 注意: Binyomin Posen ,董事、首席执行官和首席财务官 电子邮件:[受电子邮件保护] 论董事会的职责 Binyomin Posen 首席执行官、首席财务官兼董事 本公司的证券没有,也不会根据经修订的1933年美国证券法进行注册,在没有美国注册或适用的美国注册要求豁免的情况下,不得在美国境内或向美国人或为美国人的账户或利益提供或出售。本新闻稿不构成出售要约或招揽收购要约,亦不会在美国或任何其他司法权区出售证券,而有关要约、招揽或出售将属非法。 CSE 并未以任何方式根据建议交易的优点行事,亦未批准或不批准本新闻稿的内容。 本新闻稿中所载有关欣德兰的所有信息均由本公司提供,本新闻稿中有关欣德思、合成及 Cedar 的所有信息均由 Novachem 提供,以纳入本新闻稿,而欣德兰及其董事及高级职员已依赖 Novachem 获取有关该等各方的任何信息。 本新闻稿载有有关建议交易之时间及完成、本公司、新思维及结果发行人之未来营运之前瞻性陈述及并非历史事实之其他陈述。前瞻性陈述通常按“意愿”、“可能”、“应该”、“预期”、“预期”和类似表述等术语进行识别。本新闻稿所载的除历史事实陈述以外的所有陈述,包括但不限于有关建议交易及本公司、新思维及结果发行人未来计划及目标的陈述,均为涉及风险及不明朗因素的前瞻性陈述。无法保证此类报表将被证明是准确的,实际结果和未来事件可能与此类报表中预期的结果存在重大差异。可能导致实际结果与本公司、新思维和结果发行方的预期存在重大差异的重要因素包括未能满足上述建议交易完成的条件以及本公司提交的文件中不时详述的其他风险。新思维与证券监管结果发行人。 读者应注意,在准备任何前瞻性信息时使用的假设可能被证明是不正确的。由于许多已知和未知的风险、不确定性和其他因素,其中许多因素超出了本公司、 Novartin 和结果发行方的控制,事件或情况可能导致实际结果与预测结果存在重大差异。因此,本公司、 Novartmine 及结果发行人不能保证建议交易将按本协议所披露的条款及时间或全部完成。读者应注意不要过分依赖任何前瞻性信息。虽然管理层在编制时认为这些资料合理,但可能证明这些资料不正确,实际结果可能与预期结果有重大差异。本新闻稿中包含的前瞻性声明明确符合本警示性声明。本新闻稿所载的前瞻性陈述乃于本新闻稿刊发日期作出,而本公司、 Synthesis 、 Novartin 及结果发行人将根据加拿大证券法的明确规定,更新或公开修订所载的任何前瞻性陈述。 这篇文章由 CFN Enterprises Inc .( OTCQB : CNFN )出版, CFN Media 是该行业领先的代理机构和数字金融媒体网络,致力于新兴的 CBD 和合法大麻行业。致电+1(833)420-CNFN 获取更多信息。

以上中文文本为机器翻译,存在不同程度偏差和错误;偶尔因源网页结构局限,内容无法一次完整呈现。请理解并参考原站原文阅读。

阅读原文